news & events
evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
Abstract Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb uptake on PET. Target-specific binding in tumours is of main interest; however, non-specific irreversible uptake may also be present,...
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
Introduction 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and non-specific...
Poster presentations during the EMIM 2024 in Porto
During the annual European Molecular Imaging Meeting (EMIM) in Porto, nine researchers of the Immune-Image consortium presented their promising research during the poster presentations. In this article, we will give a brief summary of each presentation. Identification...
How to obtain the image‑derived blood concentration from 89Zr‑immuno‑PET scans
ABSTRACT Background PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood. Measuring activity concentrations...
An Immune-Image roundtable discussion: How can we improve an patient journey?
The Immune-Image project develops methods for visualizing the immune response before, during and after immunotherapy by means of whole-body PET imaging/immune cell imaging. This provides a supportive approach for the improvement of immunotherapies and personalised...
Unveiling the potential of a macrophage-targeted PET tracer: A first-in-human study
Introduction The human immune system contains a complex network of cells and organs, each with their own unique functions. Within this intricate tapestry, macrophages play an indispensable role займ без проверки кредитной истории. These immune cells are involved in a...
The Immune-Image patient panel
Managing expectations: an insight in the perspective of patients, patient advocates and caregivers on the ideal setup of the Immune-Image patient panel Adding an extra perspective: the patients One important aspect of large European consortia projects such as...
Checkpoint inhibitors and their role in the Immune-Image project
The immune system is our body's natural defense mechanism against diseases, including cancer. It has evolved to recognize and eliminate abnormal cells before they can cause harm. However, cancer cells often find ways to evade the immune system's attacks, allowing them...
Optical Imaging in relation to the Immune-Image Project
The Immune-Image project is a cutting-edge research effort that aims to develop innovative imaging techniques for visualizing immune responses in vivo. The project utilizes a variety of imaging modalities, including PET, MRI, and optical imaging, to gain insights into...
Personalized Medicine and the Immune-Image Project
Personalized medicine is an approach to healthcare that seeks to provide tailored treatment based on an individual’s unique characteristics, including their genetic makeup, lifestyle, and environmental factors. This approach is becoming increasingly important in the...
Patient input wanted: designing Immune-Image panel for cancer/inflammatory diseases
Calls on cancer/inflammatory diseases patients to share their thoughts on the preferred design of a patient panel ttopstart, one of the partners in the Immune-Image projects, and the Immune-Image consortium have developed a questionnaire to better understand the...
PET Imaging: A powerful tool for the Immune-Image project
Positron Emission Tomography (PET), is a powerful imaging technique that allows researchers to study the activity of cells and tissues within the body. This imaging modality has been widely used in the medical field to diagnose and monitor a variety of diseases,...
Immune-Image explores a new strategy for imaging CAR-T Cells
CAR-T cells, or chimeric antigen receptor T cells, are a type of immunotherapy that has shown great success in treating a subset of blood cancers. In this therapy, the patient’s own cells are genetically modified to recognize and target specific proteins on cancer...
Interview Andreas Jacobs – Leader work package 5
Andreas Jacobs from the University of Münster is leading work package 5 of the Immune-Image project together with Michael Schäfers of the Univerity of Münster and Ian Wilson of ImaginAb. In this work package they research the implementation of immunotracers for...
Meet the partner: ttopstart
Sigrid van Dorp is working as a consultant at ttopstart and has a background in public health and healthcare management. Within the Immune-Image project, ttopstart is part of work package 1 which focuses on management, coordination, dissemination and sustainability....
Researchers of Immune-Image reported about their recent scientific findings at EMIM2023 in Salzburg
EMIM 2023 On 14-17 March the 18th European Molecular Imaging Meeting (EMIM) took place in the heart of Salzburg, the city of Mozart. The focus was on quantification in molecular imaging, cellular imaging, x-ray/lung imaging, neuroimaging, and hyperpolarized MRI....
18th European Molecular Imaging Meeting (EMIM) in Salzburg
EMIM 2023 From 14-17 March the 18th European Molecular Imaging Meeting (EMIM) will take place in the world-famous Mirabell park gardens in the heart of Salzburg, the city of Mozart. The focus will be on quantification in molecular imaging, cellular imaging, x-ray/lung...
The Immune-Image activities of 2022 in a nutshell
At Immune-Image we haven’t sit still! Here in a nutshell what the Immune-Image project has done in 2022.
Interview Manfred Kneilling
Manfred Kneilling from the University of Tübingen is leading work package 4 of the Immune-Image project together with Bastian Zinnhardt from Roche. In this work package they evaluate the specificity and suitability of new immunotracers targeting different immune cells...
Meet the patient: Tom van der Wal
We interviewed Tom van der Wal from The Netherlands about his experiences with immunotherapy. Tom has Multiple Myeloma (Kahler) and was diagnosed in 2016, treated in VUmc Amsterdam, and was in remission in 2017. Unfortunately, the Multiple Myeloma returned in 2021. We...